Sinovac Biotech Ltd. (SVA) is currently trading at $6.47 with a Wall Street consensus price target of $3.52, which is 45.6% below the current price over the next 12 months. 6 analysts currently cover SVA, with a consensus rating of Buy - 50% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $6.0, while the most cautious has a target of $1.5.
SVA operates in the Unknown sector with a market capitalisation of N/A. The stock is up 0.0% year-to-date and is currently trading near the upper end of its 52-week range of $6.47 – $6.47.
Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.
Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.
StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.
View Full Rankings →